News
5d
Zacks Investment Research on MSNPCRX Doses First Patient in Phase II PCRX-201 Gene Therapy StudyPacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...
Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a ...
Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...
Proper motor function depends on an intact nerve complex to conduct impulses between the central and peripheral nervous systems. Neurons, consisting of are incapable of undergoing mitosis after birth.
fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management ...
It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
Complete brachial plexus block was achieved in 34 patients (83% ... No instances of systemic toxicity, hematomas, or nerve injury from the block were noted. Accesses placed included 20 ...
1d
Zacks.com on MSNPCRX Stock Soars on Exparel Patent Settlement With Generic PlayersPacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results